Glucose News and Research

RSS

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.

2 Nov 2011

NIH-funded project to discover biomarkers for type 2 diabetes

Arizona State University will lead a four-year, $5 million expanded initiative sponsored by the National Institutes of Health to discover proteins, or biomarkers, to help predict cardiovascular disease and to assess potential new treatments in people with type 2 diabetes.

2 Nov 2011

Positive results from DARA's DB959 Phase 1b study on type 2 diabetes

DARA BioSciences, Inc., announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in development for the treatment of type 2 diabetes.

2 Nov 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

Specific metabolic disturbances precede children's progression to Type 1 diabetes

New potential avenues for early disease detection and prevention: A study led by Matej Orešič from VTT Technical Research Centre of Finland suggests that autoimmune diabetes is preceded by diminished gut microbial diversity of the Clostridium leptum subgroup, elevated plasma leptin and enhanced glucose-stimulated insulin secretion.

29 Oct 2011

Dietary intervention in adolescence benefits glycemic control and blood pressure long-term

A recent study has found that a childhood behavioral intervention to lower dietary intake of total fat and saturated fat and increase consumption of foods that are good sources of dietary fiber resulted in significantly lower fasting plasma glucose levels and lower systolic blood pressure when study participants were re-evaluated in young adulthood.

28 Oct 2011

Social stressors around the transition into adulthood sow seeds of disease in middle age

Being hard up socially and financially during adolescence and early adulthood takes its toll on the body, and leads to physiological wear and tear in middle aged men and women, irrespective of how tough things have been in the interim. According to Dr. Per E. Gustafsson from Umeå University in Sweden and colleagues, experience of social and material stressors around the time of transition into adulthood is linked to a rise in disease risk factors in middle age, including higher blood pressure, body weight and cholesterol.

28 Oct 2011

Innovative trial project of MD-Logic Artificial Pancreas takes place in Israel

At the initiative, and under the leadership of specialists in the Jesse Z and Sara Lea Shaffer Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children's Medical Center, an innovative trial project of the MD-Logic Artificial Pancreas (MDLAP) has successfully taken place in Israel.

27 Oct 2011

International diabetes researchers to engineer artificial pancreas system

The National Institutes for Health (NIH) have awarded $4.5 million to a group of international diabetes researchers to engineer an artificial pancreas system that will monitor and adapt to the body's complex real-time changes in behavior and physiology.

27 Oct 2011

Insulin resistance paradox

Obesity and insulin resistance are almost inevitably associated with increases in lipid accumulation in the liver, a serious disease that can deteriorate to hepatitis and liver failure. A real paradox in understanding insulin resistance is figuring out why insulin-resistant livers make more fat. Insulin resistance occurs when the body does a poor job of lowering blood sugars.

27 Oct 2011

U-M researchers to study new approach in halting downward spiral of diabetes

University of Michigan Health System researchers will use a $3.5 million federal grant to study a new approach in halting the downward spiral of diabetes.

24 Oct 2011

SCI patients with autonomic dysfunction more likely to develop heart disease

New research from the Heart and Stroke Foundation and the Christopher and Dana Reeve Foundation may help explain why people with spinal cord injury (SCI) have a higher risk of developing heart disease.

24 Oct 2011

Cardiac rehab boosts longevity, especially in patients with lowest fitness levels

Cardiac rehabilitation boosts longevity, especially in patients with the lowest fitness levels, Dr. Billie-Jean Martin today told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

24 Oct 2011

Women hospital staff working night shifts may face increased risk of heart disease

Women hospital staff working night shifts may be compromising their own health as they try to improve the health of patients, Dr. Joan Tranmer told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

24 Oct 2011

Higher diabetes rates in African American women after GDM

African American women who develop gestational diabetes mellitus during pregnancy face a 52 percent increased risk of developing diabetes in the future compared to white women who develop GDM during pregnancy, according to a Kaiser Permanente study published online in the journal Diabetologia.

21 Oct 2011

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Common link between Type 2 diabetes and autism

A review of the genetic and biochemical abnormalities associated with autism reveals a possible link between the widely diagnosed neurological disorder and Type 2 diabetes, another medical disorder on the rise in recent decades.

20 Oct 2011

Accera identifies genetic profile of AD patients with heightened response to Axona

Accera, Inc., a biotech company specializing in cognitive health, announced today that it has identified the genetic profile of Alzheimer’s disease (AD) patients who have a high probability of responding to Axona (AC-1202), a prescription medical food product available at pharmacies nationwide.

18 Oct 2011

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc., and Takeda Global Research & Development Centre (Europe), Ltd., announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes.

18 Oct 2011